To donate by check, phone, or other method, see our More Ways to Give page.
A person uses Ozempic on November 2, 2023, in Madrid, Spain.
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," one doctor said.
As the U.S. Senate prepares for a hearing on Novo Nordisk overcharging Americans for Ozempic and Wegovy, Sen. Bernie Sanders on Monday released a letter from 253 health professionals asking Congress to take on the "exorbitant prices set by manufacturers" for non-insulin diabetes and weight loss medications.
The clinicians wrote that drugs including "semaglutide (marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss) and... tirzapetide (marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight loss) have been revolutionary in the management of chronic conditions of diabetes and obesity."
"However, even the most transformative medications cannot help our patients if they cannot afford them," states the letter, which is addressed to Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP), and Sen. Bill Cassidy (R-La.), the panel's ranking member.
"If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
"Studies have shown that semaglutide can be manufactured for as little as nearly $5 per month, substantially lower than the current U.S. list price of $968 for Ozempic or $1,349 per month for Wegovy," the letter notes. "In contrast, Novo Nordisk has set the price of Wegovy at $92 in the United Kingdom and $186 in Denmark, clearly demonstrating that these drugs are being priced unfairly for our U.S. patients."
The health providers stressed that "for patients, these are not one-off prices they shoulder, but potentially lifelong costs they will need to consider. For obesity, the drugs work while patients take them, but once off treatment, studies have found that patients regain the weight."
"Patients in the U.S. face multiple hurdles in accessing the drugs, which we as prescribers do our best to help them navigate," they explained, detailing issues faced by people who have private insurance, Medicare and Medicaid coverage, and no insurance. "Lack of coverage, supply shortages, and the unreasonable sticker prices of these medications are pushing patients to consider alternative options, which are often unsafe."
"We want our patients to be able to access medications that can improve their health and quality of life, but we do not want to rob the American taxpayers to line the pockets of the pharmaceutical manufacturers," the clinicians concluded. "Senators, we are asking you to do everything in your power to bring down the price of these novel diabetes and obesity drugs. Our patients deserve to have the best options available to them at a fair price."
Echoing the letter in a Monday statement, Dr. Kasia Lipska, a practicing endocrinologist and diabetes researcher at the Yale School of Medicine in Connecticut, said that "the exorbitant prices that manufacturers are asking my patients to pay for these novel diabetes and obesity medications are simply unacceptable."
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," Lipska continued. "These are life-changing treatments that should be available to my patients and everyone who needs them, not just those who can afford to pay."
Dr. Elizabeth Dewey, another letter signatory who practices family medicine in Greensboro, North Carolina, said that in her state, "we have been struggling all year with lack of coverage for weight loss medications."
"When our state plan and large employers dropped coverage for weight loss medications earlier this year, patients were left without treatment," Dewey explained. "Those who wanted to continue on the medications could pay cash. But for most patients, paying hundreds of dollars without insurance coverage is not affordable. Even with drug company coupons or discounts on certain doses, these treatments are still unattainable for most of my patients."
Sanders, who launched a probe into Denmark-based Novo Nordisk back in April, welcomed the letter, saying that "doctors across this country are sick and tired of seeing their patients ripped off by giant pharmaceutical companies."
"There is no rational reason, other than greed, for Novo Nordisk to charge Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany," he argued. "Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany."
"Doctors agree," he added. "If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
The Senate HELP Committee hearing on Capitol Hill is scheduled for 10:00 am on Tuesday, September 24.
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
As the U.S. Senate prepares for a hearing on Novo Nordisk overcharging Americans for Ozempic and Wegovy, Sen. Bernie Sanders on Monday released a letter from 253 health professionals asking Congress to take on the "exorbitant prices set by manufacturers" for non-insulin diabetes and weight loss medications.
The clinicians wrote that drugs including "semaglutide (marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss) and... tirzapetide (marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight loss) have been revolutionary in the management of chronic conditions of diabetes and obesity."
"However, even the most transformative medications cannot help our patients if they cannot afford them," states the letter, which is addressed to Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP), and Sen. Bill Cassidy (R-La.), the panel's ranking member.
"If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
"Studies have shown that semaglutide can be manufactured for as little as nearly $5 per month, substantially lower than the current U.S. list price of $968 for Ozempic or $1,349 per month for Wegovy," the letter notes. "In contrast, Novo Nordisk has set the price of Wegovy at $92 in the United Kingdom and $186 in Denmark, clearly demonstrating that these drugs are being priced unfairly for our U.S. patients."
The health providers stressed that "for patients, these are not one-off prices they shoulder, but potentially lifelong costs they will need to consider. For obesity, the drugs work while patients take them, but once off treatment, studies have found that patients regain the weight."
"Patients in the U.S. face multiple hurdles in accessing the drugs, which we as prescribers do our best to help them navigate," they explained, detailing issues faced by people who have private insurance, Medicare and Medicaid coverage, and no insurance. "Lack of coverage, supply shortages, and the unreasonable sticker prices of these medications are pushing patients to consider alternative options, which are often unsafe."
"We want our patients to be able to access medications that can improve their health and quality of life, but we do not want to rob the American taxpayers to line the pockets of the pharmaceutical manufacturers," the clinicians concluded. "Senators, we are asking you to do everything in your power to bring down the price of these novel diabetes and obesity drugs. Our patients deserve to have the best options available to them at a fair price."
Echoing the letter in a Monday statement, Dr. Kasia Lipska, a practicing endocrinologist and diabetes researcher at the Yale School of Medicine in Connecticut, said that "the exorbitant prices that manufacturers are asking my patients to pay for these novel diabetes and obesity medications are simply unacceptable."
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," Lipska continued. "These are life-changing treatments that should be available to my patients and everyone who needs them, not just those who can afford to pay."
Dr. Elizabeth Dewey, another letter signatory who practices family medicine in Greensboro, North Carolina, said that in her state, "we have been struggling all year with lack of coverage for weight loss medications."
"When our state plan and large employers dropped coverage for weight loss medications earlier this year, patients were left without treatment," Dewey explained. "Those who wanted to continue on the medications could pay cash. But for most patients, paying hundreds of dollars without insurance coverage is not affordable. Even with drug company coupons or discounts on certain doses, these treatments are still unattainable for most of my patients."
Sanders, who launched a probe into Denmark-based Novo Nordisk back in April, welcomed the letter, saying that "doctors across this country are sick and tired of seeing their patients ripped off by giant pharmaceutical companies."
"There is no rational reason, other than greed, for Novo Nordisk to charge Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany," he argued. "Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany."
"Doctors agree," he added. "If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
The Senate HELP Committee hearing on Capitol Hill is scheduled for 10:00 am on Tuesday, September 24.
As the U.S. Senate prepares for a hearing on Novo Nordisk overcharging Americans for Ozempic and Wegovy, Sen. Bernie Sanders on Monday released a letter from 253 health professionals asking Congress to take on the "exorbitant prices set by manufacturers" for non-insulin diabetes and weight loss medications.
The clinicians wrote that drugs including "semaglutide (marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss) and... tirzapetide (marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight loss) have been revolutionary in the management of chronic conditions of diabetes and obesity."
"However, even the most transformative medications cannot help our patients if they cannot afford them," states the letter, which is addressed to Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP), and Sen. Bill Cassidy (R-La.), the panel's ranking member.
"If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
"Studies have shown that semaglutide can be manufactured for as little as nearly $5 per month, substantially lower than the current U.S. list price of $968 for Ozempic or $1,349 per month for Wegovy," the letter notes. "In contrast, Novo Nordisk has set the price of Wegovy at $92 in the United Kingdom and $186 in Denmark, clearly demonstrating that these drugs are being priced unfairly for our U.S. patients."
The health providers stressed that "for patients, these are not one-off prices they shoulder, but potentially lifelong costs they will need to consider. For obesity, the drugs work while patients take them, but once off treatment, studies have found that patients regain the weight."
"Patients in the U.S. face multiple hurdles in accessing the drugs, which we as prescribers do our best to help them navigate," they explained, detailing issues faced by people who have private insurance, Medicare and Medicaid coverage, and no insurance. "Lack of coverage, supply shortages, and the unreasonable sticker prices of these medications are pushing patients to consider alternative options, which are often unsafe."
"We want our patients to be able to access medications that can improve their health and quality of life, but we do not want to rob the American taxpayers to line the pockets of the pharmaceutical manufacturers," the clinicians concluded. "Senators, we are asking you to do everything in your power to bring down the price of these novel diabetes and obesity drugs. Our patients deserve to have the best options available to them at a fair price."
Echoing the letter in a Monday statement, Dr. Kasia Lipska, a practicing endocrinologist and diabetes researcher at the Yale School of Medicine in Connecticut, said that "the exorbitant prices that manufacturers are asking my patients to pay for these novel diabetes and obesity medications are simply unacceptable."
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," Lipska continued. "These are life-changing treatments that should be available to my patients and everyone who needs them, not just those who can afford to pay."
Dr. Elizabeth Dewey, another letter signatory who practices family medicine in Greensboro, North Carolina, said that in her state, "we have been struggling all year with lack of coverage for weight loss medications."
"When our state plan and large employers dropped coverage for weight loss medications earlier this year, patients were left without treatment," Dewey explained. "Those who wanted to continue on the medications could pay cash. But for most patients, paying hundreds of dollars without insurance coverage is not affordable. Even with drug company coupons or discounts on certain doses, these treatments are still unattainable for most of my patients."
Sanders, who launched a probe into Denmark-based Novo Nordisk back in April, welcomed the letter, saying that "doctors across this country are sick and tired of seeing their patients ripped off by giant pharmaceutical companies."
"There is no rational reason, other than greed, for Novo Nordisk to charge Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany," he argued. "Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany."
"Doctors agree," he added. "If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
The Senate HELP Committee hearing on Capitol Hill is scheduled for 10:00 am on Tuesday, September 24.